We are live on ! Find out more
VMI

VHCP Management II Portfolio holdings

AUM $379M
1-Year Est. Return 421.62%
This Fund
S&P 500
This Quarter Est. Return
+24.32%
1 Year Est. Return
+421.62%
3 Year Est. Return
+2,333.62%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$334M
AUM Growth
-$80.3M
Cap. Flow
-$138M
Cap. Flow %
-41.24%
Top 10 Hldgs %
87.99%
Holding
24
New
7
Increased
3
Reduced
2
Closed
6

Top Buys

Rank Stock Value
1
TCDA
Tricida, Inc. Common Stock
TCDA
+$26.9M
2
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$11.6M
3
DBVT
DBV Technologies
DBVT
+$10.4M
4
KDMN
Kadmon Holdings, Inc.
KDMN
+$5.51M
5
MRNS
Marinus Pharmaceuticals, Inc
MRNS
+$1.91M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$128M
2
ANAB icon
AnaptysBio
ANAB
+$18.8M
3
GYRE icon
Gyre Therapeutics
GYRE
+$14.3M
4
VYNE icon
VYNE Therapeutics
VYNE
+$12.8M
5
ASND icon
Ascendis Pharma A/S
ASND
+$5.39M

Sector Composition

Rank Sector Weight
1 Healthcare 96.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ECYT
1
DELISTED
Endocyte, Inc. Common Stock
ECYT
$59.3M 17.76%
4,300,000
– –
BHVN
2
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$55.9M 16.74%
1,415,391
+25,000
+2% +$793K
OBSV
3
DELISTED
ObsEva SA Ordinary Shares
OBSV
$34.1M 10.21%
2,252,460
+108,617
+5% +$1.44M
ASND icon
4
Ascendis Pharma A/S
ASND
$17.1B
$33.5M 10.04%
504,210
-81,985
-14% -$5.39M
ARGX icon
5
argenx
ARGX
$53.8B
$29M 8.68%
346,792
– –
TCDA
6
DELISTED
Tricida, Inc. Common Stock
TCDA
$28.8M 8.62%
+962,696
New +$26.9M
ZGNX
7
DELISTED
Zogenix, Inc.
ZGNX
$16M 4.79%
362,010
– –
BCRX icon
8
BioCryst Pharmaceuticals
BCRX
$2.36B
$14.1M 4.23%
2,464,241
+243,270
+11% +$1.34M
DBVT
9
DBV Technologies
DBVT
$870M
$12M 3.6%
+46,315
New +$10.4M
KNSA icon
10
Kiniksa Pharmaceuticals
KNSA
$4.92B
$11.1M 3.32%
+639,230
New +$11.6M
BLPH
11
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$10M 3.01%
276,625
– –
MNTA
12
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$8.69M 2.6%
425,000
– –
SPRO icon
13
Spero Therapeutics
SPRO
$91.5M
$6.95M 2.08%
474,015
-11,600
-2% -$148K
KDMN
14
DELISTED
Kadmon Holdings, Inc.
KDMN
$5.63M 1.69%
+1,411,428
New +$5.51M
RARX
15
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$5.42M 1.62%
544,612
– –
MRNS
16
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$2.44M 0.73%
+86,310
New +$1.91M
APLS
17
DELISTED
Apellis Pharmaceuticals
APLS
$654K 0.2%
+29,710
New +$683K
CCXI
18
DELISTED
ChemoCentryx, Inc.
CCXI
$304K 0.09%
+23,064
New +$276K
ANAB icon
19
AnaptysBio
ANAB
$1.72B
– –
-180,950
Closed -$18.8M
GYRE icon
20
Gyre Therapeutics
GYRE
$675M
– –
-73,817
Closed -$14.3M
SVRA icon
21
Savara
SVRA
$1.13B
– –
-119,840
Closed -$1.1M
VYNE icon
22
VYNE Therapeutics
VYNE
$25.4M
– –
-4,722
Closed -$12.8M
AVXS
23
DELISTED
AveXis, Inc. Common Stock
AVXS
– –
-1,035,657
Closed -$128M

Similar funds

ACPU
Arrowgrass Capital Partners (US) Dover, Delaware $380M AUM 20.87% 1-Year Est. Return
PI
PHH Investments Addison, Texas $378M AUM 19.74% 1-Year Est. Return
SC
Southside Capital Miami Beach, Florida $382M AUM 30.29% 1-Year Est. Return
FFSOTS
Fiduciary Financial Services of The Southwest Dallas, Texas $382M AUM 25.98% 1-Year Est. Return
PC
Passport Capital San Francisco, California $394M AUM 50.67% 1-Year Est. Return
WC
Whitnell & Co Oak Brook, Illinois $326M AUM 25.97% 1-Year Est. Return
VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
LB
Landmark Bank Columbia, Missouri $444M AUM 30.12% 1-Year Est. Return

VHCP Management II's Q2 2018 Portfolio in Review

As of Q2 2018, VHCP Management II held 24 positions worth $334M, down 19% from $414M the previous quarter. Its ten largest holdings account for 88% of the portfolio.

VHCP Management II withdrew a net $138M in Q2 2018, closing 6 positions and reducing 2 holdings. Its most notable exit was AveXis, Inc. Common Stock, an estimated $128M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier.

Against the trend, VHCP Management II opened a new position in Tricida, Inc. Common Stock worth $28.8M.

  • VHCP Management II's largest Q2 2018 buy was Tricida, Inc. Common Stock: 962,696 shares worth $28.8M.
  • VHCP Management II added most to ObsEva SA Ordinary Shares in Q2 2018, an estimated $1.44M increase.
  • VHCP Management II's biggest Q2 2018 reduction was Ascendis Pharma A/S, cutting an estimated $5.39M.
  • VHCP Management II fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $128M.
  • VHCP Management II's ten largest holdings make up 88% of its $334M portfolio in Q2 2018.
  • VHCP Management II opened 7 new positions and closed 6 in Q2 2018.
  • VHCP Management II's portfolio value fell 19% quarter-over-quarter to $334M.

Based on VHCP Management II's 13F filing for Q2 2018, filed 13 Aug 2018.